Role of new antifungal agents in prophylaxis of mycoses in high risk patients

被引:20
|
作者
van Burik, JAH [1 ]
机构
[1] Univ Minnesota, Minneapolis, MN 55455 USA
关键词
aerosolized amphotericin; fluconazole; fungal infection; hematopoietic stem cell transplantation; itraconazole; liver transplantation; lung transplantation; micafungin; mycoses; pancreas transplantation; posaconazole; prophylaxis; voriconazole;
D O I
10.1097/01.qco.0000185984.57135.ad
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of review For pancreas, liver, and hematopoietic stem cell transplant recipients, no antifungal prophylaxis led to a high rate of and high morbidity from fungal infection. With the use of fluconazole as prophylaxis since the early 1990s, there have been shifts in the types of infecting fungal pathogens, documentation of resistance among fungal organisms, and changes in transplant practices. The aim of this article is to review recent clinical trials regarding antifungal chemoprophylaxis among several populations of high risk patients. Recent findings Itraconazole, micafungin, and posaconazole have been studied as alternatives to fluconazole prophylaxis. Itraconazole showed no dramatic improvement over fluconazole as prophylaxis during liver and hematopoietic stem cell transplantation, primarily due to gastrointestinal side effects. In addition, detrimental changes to cyclophosphamide metabolism were noted for hematopoietic stem cell transplant recipients. Micafungin was superior to fluconazole during the pre-engraftment period of hematopoietic stem cell transplantation, because it was able to prevent mold infections, required less switches to empirical antifungal therapy, and functioned as well as fluconazole in preventing yeast infections. Posaconazole was compared to fluconazole during a 16-week prophylaxis period during graft-versus-host disease, but results of this study are still forthcoming. Aerosolized amphotericin products appear to be safe for lung transplant recipients. Summary Fluconazole remains the standard agent for prophylaxis against invasive fungal infections for pancreas, liver, and hematopoietic stem cell transplant recipients. Micafungin is superior to fluconazole with minimal toxicity for use in the pre-engraftment period of hematopoietic stem cell transplantation. The optimal agent for prophylaxis later following transplant, if mold coverage is desired during prolonged immunosuppression, has not been determined.
引用
收藏
页码:479 / 483
页数:5
相关论文
共 50 条
  • [31] Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease
    Bochennek, K.
    Balan, A.
    Mueller-Scholden, L.
    Becker, M.
    Farowski, F.
    Mueller, C.
    Groll, A. H.
    Lehrnbecher, T.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (05) : 1527 - 1530
  • [32] Clinical efficacy and management of primary antifungal prophylaxis with posaconazole in high-risk haematology patients
    Sanchez-Ortega, I.
    Cuesta, I.
    Patino, B.
    Parody, R.
    Arnan, M.
    Fernandez de Sevilla, A.
    Gudiol, C.
    Ayats, J.
    Cuenca-Estrella, M.
    Duarte, R. F.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 : S318 - S319
  • [33] Micafungin as Antifungal Prophylaxis in High-Risk Liver Transplant Patients: A Randomised Multicentre Trial
    Saliba, F.
    Pascher, A.
    Cointault, O.
    Laterre, P.
    De Waele, J.
    Cillo, U.
    Cervera, C.
    Tweddle, L.
    Karas, A.
    Fischer, L.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 770 - 770
  • [34] Is there a role for antifungal prophylaxis in patients undergoing penile prosthesis surgery?
    Siddiqui, Zain
    Pearce, Ian
    Modgil, Vaibhav
    [J]. BJU INTERNATIONAL, 2022, 129 : 67 - 67
  • [35] Role of homoserine transacetylase as a new target for antifungal agents
    Nazi, Ishac
    Scott, Adam
    Sham, Anita
    Rossi, Laura
    Williamson, Peter R.
    Kronstad, James W.
    Wright, Gerard D.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (05) : 1731 - 1736
  • [36] IS THERE A ROLE FOR CORTICOSTEROID PROPHYLAXIS IN PATIENTS AT INCREASED RISK OF ADVERSE REACTIONS TO INTRAVASCULAR CONTRAST AGENTS
    DAWSON, P
    SIDHU, PS
    [J]. CLINICAL RADIOLOGY, 1993, 48 (04) : 225 - 226
  • [37] Evaluation on 'real life' prescriptions of antifungal prophylaxis in high risk patients: preliminary results from a prospective survey Evaluation on 'real life' prescriptions of antifungal prophylaxis in high risk patients: preliminary results from a prospective survey
    Caira, M.
    Busca, A.
    Melillo, L.
    Candoni, A.
    Caramatti, C.
    Specchia, G.
    Fanci, R.
    Rossi, G.
    Cattaneo, C.
    Vacca, A.
    Quintavalle, C.
    Picardi, M.
    Mitra, M. E.
    Delia, M.
    Landini, B.
    Gasbarrino, C.
    Invernizzi, R.
    Salutari, P.
    Martino, B.
    Garzia, M. G.
    Chierichini, A.
    Venditti, A.
    Nadali, G.
    Luppi, M.
    Leone, G.
    Nosari, A. M.
    Aversa, F.
    Pagano, L.
    Vianelli, N.
    [J]. MYCOSES, 2011, 54 : 89 - 90
  • [38] The role of murine models in the development of antifungal therapy for systemic mycoses
    Graybill, JR
    [J]. DRUG RESISTANCE UPDATES, 2000, 3 (06) : 364 - 383
  • [39] Outcomes of antifungal prophylaxis in high-risk liver transplant recipients
    Hadley, S.
    Huckabee, C.
    Pappas, P. G.
    Daly, J.
    Rabkin, J.
    Kauffman, C. A.
    Merion, R. M.
    Karchmer, A. W.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (01) : 40 - 48
  • [40] Revisiting Antifungal Prophylaxis in High- Risk Liver Transplant Recipients
    Huprikar, S.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (12) : 2683 - 2684